Stockscreener 앱 받기
0.00
100.00%
-1.71
전일 마감가:
$1.71
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$4.36M
수익:
-
순이익/손실:
$-35.80M
주가수익비율:
0.00
EPS:
-2.97
순현금흐름:
$-37.18M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$38.10
Aptose Biosciences Inc Stock (APTO) Company Profile
명칭
Aptose Biosciences Inc
전화
310-849-8060
주소
66 WELLINGTON STREET WEST, SUITE 5300, TORONTO, ON
APTO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APTO
Aptose Biosciences Inc
|
0.00 | 4.36M | 0 | -35.80M | -37.18M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Aptose Biosciences Inc Stock (APTO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-10-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-22 | 개시 | Alliance Global Partners | Buy |
| 2020-02-20 | 개시 | Maxim Group | Buy |
| 2020-02-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-09 | 개시 | Piper Sandler | Overweight |
| 2019-03-01 | 개시 | RBC Capital Mkts | Outperform |
| 2018-11-16 | 개시 | B. Riley FBR | Buy |
| 2017-12-13 | 재확인 | H.C. Wainwright | Buy |
| 2017-10-23 | 재개 | ROTH Capital | Buy |
| 2017-09-07 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2017-06-08 | 개시 | Rodman & Renshaw | Neutral |
모두보기
Aptose Biosciences Inc 주식(APTO)의 최신 뉴스
(APS) Equity Trading Insights (APS:CA) - news.stocktradersdaily.com
Aptose Announces Auditor Not Standing for Re-Appointment - The Manila Times
Major Red Flag: KPMG Abandons Aptose Over Complex Financial Instrument Controls - Stock Titan
Aptose Biosciences Inc. - MENAFN.com
Stocks In Play: Aptose Biosciences Inc. - Barchart.com
Aptose Biosciences to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference - Nasdaq
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference - The Manila Times
Aptose Reveals Latest Progress on Revolutionary Triple-Drug Therapy for Untreated AML Patients - Stock Titan
Aptose Biosciences announces change in accounting firm By Investing.com - Investing.com India
Aptose Biosciences announces change in accounting firm - Investing.com
(APS) Daily Stock Insights (APS:CA) - news.stocktradersdaily.com
Objective long/short (APS) Report (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences (NASDAQ:APTO) Earns Sell Rating from Analysts at StockNews.com - Defense World
(APS) Technical Data (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com - Defense World
Aptose Biosciences secures $25 million equity facility - MSN
Aptose Biosciences shares to delist from Nasdaq as of April 2 - Yahoo Finance
APTO stock touches 52-week low at $1.86 amid sharp annual decline - Investing.com Australia
APTO stock touches 52-week low at $1.86 amid sharp annual decline By Investing.com - Investing.com South Africa
Stock Market Shakes As Major Firms See Sharp Declines - Finimize
Nasdaq Surges 1%; US Construction Spending Rises In February - Benzinga
Why Aptose Biosciences (APTO) Stock Is Down Over 40% - Benzinga
Dow Dips Over 400 Points; ISM Manufacturing PMI Falls In March - Benzinga
Aptose Biosciences Says Shares to Be Delisted From Nasdaq - MarketScreener
Aptose Biosciences to be delisted from Nasdaq By Investing.com - Investing.com South Africa
Aptose Biosciences to be delisted from Nasdaq - Investing.com
Aptose Biosciences to Delist from Nasdaq in April - TipRanks
Aptose shares tumble following Nasdaq delisting decision By Investing.com - Investing.com Canada
Aptose Common Shares to Delist from Nasdaq as of April 2, 2025 - The Manila Times
Aptose Faces Nasdaq Exit: What This Means for Investors and Trading Options - Stock Titan
H.C. Wainwright raises Aptose stock target to $6, maintains Buy By Investing.com - Investing.com Canada
H.C. Wainwright raises Aptose stock target to $6, maintains Buy - Investing.com
Short Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Drops By 56.6% - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Aptose Biosciences (NASDAQ:APTO) Stock - Defense World
Aptose Biosciences price target raised to $6 from $2 at H.C. Wainwright - Yahoo Finance
Aptose Biosciences Inc. SEC 10-K Report - TradingView
Aptose Biosciences Advances AML Therapy and Strengthens Financial Position - TipRanks
Aptose Biosciences Brief: Adds Results to Date Highlight TUS Potential as an "Ideal" Third Drug to Include in AML Triplet Therapy - MarketScreener
Aptose Achieves Breakthrough in AML Treatment While Cutting Losses by 50% in 2024 - Stock Titan
Better Artificial Intelligence (AI) Stock: Nvidia vs. AMD - The Globe and Mail
Aptose Reports Year End 2024 Results and Corporate Highlights - The Manila Times
Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com - Defense World
(APS) Strategic Market Analysis (APS:CA) - news.stocktradersdaily.com
3 Evergreen Financial Stocks to Buy With $3,000 and Hold Forever - The Globe and Mail
Bleichroeder LP Significantly Reduces Holdings in Aptose Biosciences Inc - GuruFocus
Aptose Biosciences Converts Debt to Equity with Hanmi Pharmaceutical By Investing.com - Investing.com South Africa
Aptose Biosciences Converts Debt to Equity with Hanmi Pharmaceutical - Investing.com
3 Reasons to Avoid DOX and 1 Stock to Buy Instead - The Globe and Mail
Bleichroeder LP Acquires Significant Stake in Aptose Biosciences Inc - GuruFocus.com
Trend Tracker for (APS) (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences Inc (APTO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):